- Nachrichtendetail
-
17.06.2024 14:02:15 - dpa-AFX: *J&J :SUBCUTANEOUS AMIVANTAMAB BLA SUBMITTED TO FDA FOR PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Johnson & Johnson | 853260 | NYSE | 154,240 | 22.07.24 22:00:05 | -0,450 | -0,29% | 154,000 | 154,490 | 156,510 | 154,690 |
